Pages that link to "Q15410251"
Jump to navigation
Jump to search
The following pages link to avibactam (Q15410251):
Displaying 50 items.
- ceftazidime/avibactam (Q20973563) (← links)
- Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48 (Q27696191) (← links)
- Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice (Q35168955) (← links)
- Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases (Q35556737) (← links)
- Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. (Q35607743) (← links)
- Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains (Q35607885) (← links)
- Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. (Q35633146) (← links)
- Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota (Q35634838) (← links)
- Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam (Q35746006) (← links)
- Avibactam and inhibitor-resistant SHV β-lactamases (Q35746285) (← links)
- Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop (Q35847267) (← links)
- β-lactam/β-lactamase inhibitor combinations: from then to now. (Q38264182) (← links)
- Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam (Q39001350) (← links)
- Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa (Q40676639) (← links)
- In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. (Q41240109) (← links)
- Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies (Q41379541) (← links)
- In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates (Q41444740) (← links)
- In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases (Q41547467) (← links)
- In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays (Q41610058) (← links)
- In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations (Q41637675) (← links)
- In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. (Q43144149) (← links)
- Infections Caused by Carbapenem-Resistant : An Update on Therapeutic Options (Q61806026) (← links)
- Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104 (Q61967765) (← links)
- Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections (Q63318136) (← links)
- A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. (Q63572427) (← links)
- ZAVI APD ELF Protocol v2.2 (Q63595028) (← links)
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects (Q63814077) (← links)
- A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) (Q63814132) (← links)
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (Q63842856) (← links)
- Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens (Q64030290) (← links)
- Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections (Q64044897) (← links)
- Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria and (Q64078801) (← links)
- TEM-184, a Novel TEM-Derived Extended-Spectrum β-Lactamase with Enhanced Activity against Aztreonam (Q64135942) (← links)
- Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE) (Q64172168) (← links)
- Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria (Q64187703) (← links)
- Real-World Observational Study Of Zavicefta to Characterize Use Patterns (Q64187736) (← links)
- A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers (Q64635407) (← links)
- Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections (Q64637495) (← links)
- To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) (Q64641155) (← links)
- Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance (Q64644411) (← links)
- A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately (Q64646563) (← links)
- A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately (Q64648319) (← links)
- Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma (Q64660660) (← links)
- Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections (Q64716468) (← links)
- Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis (Q65341330) (← links)
- Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs) (Q65344129) (← links)
- Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs). (Q65345473) (← links)
- Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections (Q65364094) (← links)
- Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections (Q65375521) (← links)
- A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ in Combination With Aztreonam (Q66066052) (← links)